(redirected from glycopeptide)
Also found in: Thesaurus, Medical, Encyclopedia.


 (glī′kō-prō′tēn′, -tē-ĭn)
Any of a group of conjugated proteins having a carbohydrate as the nonprotein component.


(ˌɡlaɪkəʊˈprəʊtiːn) ,




(Biochemistry) any of a group of conjugated proteins containing small amounts of carbohydrates as prosthetic groups. See also mucoprotein


(ˌglaɪ koʊˈproʊ tin, -ti ɪn)

any of a group of complex proteins, as mucin, containing a carbohydrate combined with a simple protein.
Also called gly`co•pep′tide (-ˈpɛp taɪd)
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.glycoprotein - a conjugated protein having a carbohydrate component
mucin - a nitrogenous substance found in mucous secretions; a lubricant that protects body surfaces
compound protein, conjugated protein - a protein complex combining amino acids with other substances
erythropoietin - a glycoprotein secreted by the kidneys that stimulates the production of red blood cells
CD4, cluster of differentiation 4 - a glycoprotein that is found primarily on the surface of helper T cells; "CD4 is a receptor for HIV in humans"
CD8, cluster of differentiation 8 - a membrane glycoprotein that is found primarily on the surface of cytotoxic T cells
lectin - any of several plant glycoproteins that act like specific antibodies but are not antibodies in that they are not evoked by an antigenic stimulus
mucoid - any of several glycoproteins similar to mucin
References in periodicals archive ?
Due to Xenleta novel mechanism of action, the likelihood of developing resistance as well as cross resistance with the beta-lactam, fluoroquinolone, glycopeptide, macrolide, and tetracycline antibiotic classes is low.
(%) Penicillin ([dagger]) 5 (6.8) 393 (6.0) 0.99 1st-generation 2 (2.7) 445 (6.8) 0.24 cephalosporin 2nd-generation 2 (2.7) 184 (2.8) 0.99 cephalosporin 3rd-generation 26 (35.1) 1,089 (16.7) <0.01 cephalosporin 4th-generation 0 1 0.99 cephalosporin Aminoglycoside 13 (17.6) 118 (1.8) <0.01 Glycopeptide 40 (54.1) 481 (7.4) <0.01 Linezolid 6(8.1) 40 (0.6) <0.01 Carbapenem 42 (56.8) 416 (6.4) <0.01 Tetracycline 12 (16.2) 58 (0.9) <0.01 Trimethoprim- 17 (23.0) 245 (3.8) <0.01 sulfamethoxazole Lincosamide 7 (9.5) 40 (0.6) <0.01 Macrolide 1 (1.4) 286 (4.4) 0.32 Fluoroquinolone 43 (58.1) 871 (13.4) <0.01 Other 5 (6.8) 100 (1.5) <0.01 After matching Case- Control- Variable patients, n patients, = 52 n = 156 p value Ward, no.
Fortunately, vancomycin, a glycopeptide antimicrobial agent that inhibits bacterial cell wall synthesis, was discovered.
Boddy, Stefan Brase, and Nicolas Winssinger, Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics.
Vancomycin is a glycopeptide and is very popular and competent antimicrobial drug for treating MRSA infections but unfortunately resistance to vancomycin have also been reported since 1997.
It is an essential part of the surveillance system of each and every hospital setup to monitor continuously such Glycopeptide resistant CoNS infections, and to assess the antibiotic susceptibility pattern of them.
The glycosylation and high-throughput proteomics approaches were combined, resulting in a glycopeptide profiling workflow with very promising diagnostic potential.
Here, we have introduced a practical method for mapping and comparing the glycosylation patterns in rAb glycoproteins, in which glycopeptide samples prepared by in-solution or in-gel protein digestion are analyzed by LC-ESI-MS-MS.
However, the addition of an aminoglycoside to a cell wall-active agent (a [beta] lactam or a glycopeptide) increases cure rates and eradicates the organisms; moreover, this combination is synergistic and bactericidal in vitro.
Vancomycin is a glycopeptide antibiotic used for the treatment of serious infections caused by Gram-positive organism.
This study was carried out to determine antimicrobial sensitivity and detect hVISA in clinical isolates of MRSA by Glycopeptide Resistance Detection (GRD) E test.
Using antimicrobials as growth promoters in livestock production and the typical treatment for bacterial infections which is a bactericidal and synergistic mixture of a cell wall synthesis inhibitor such as a [beta]-lactam antibiotic or glycopeptide, with an aminoglycoside has been described as reasons of the emergence of bacteria with high-level resistance The typical treatment for bacterial infections is a bactericidal and synergistic mixture of a cell wall synthesis inhibitor such as a [beta]-lactam antibiotic or glycopeptide, with an aminoglycoside.